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Introduction: Necitumumab, a second-generation, recombi-
nant human immunoglobulin G1 epidermal growth
factor receptor antibody in the phase 3 SQUIRE trial
(NCT00981058), increased survival beneﬁt for patients ran-
domized to receive necitumumab plus gemcitabine-cisplatin
compared with those who received gemcitabine-cisplatin.
Here we characterize health-related quality of life (HRQoL)
and tolerability results.
Methods: A total of 1093 patients with stage IV squamous
non–small cell lung cancer were randomized 1:1 to receive
necitumumab (800 mg absolute dose intravenously [IV])
plus gemcitabine-cisplatin (gemcitabine ¼ 1250 mg/m2 IV
on days 1 and 8; cisplatin ¼ 75 mg/m2 IV on day 1) or
gemcitabine-cisplatin alone (every 21 days) for up to six
cycles. Patients receiving necitumumab plus gemcitabine-
cisplatin without disease progression continued necitumu-
mab until progression. HRQoL was measured by EasternJournal of Thoracic Oncology Vol. 11 No. 6: 808-818Cooperative Oncology Group performance status, the Lung
Cancer Symptom Scale (LCSS), and the European Quality
of Life Five-Dimensions questionnaire. Efﬁcacy and LCSS
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severity score of the LCSS. Tolerability was measured in
terms of exposure to the study treatment and adverse
events. Hospitalization rates were collected.
Results: Most patients in both study arms similarly main-
tained Eastern Cooperative Oncology Group performance
status and comparable LCSS and European Quality of Life
Five-Dimensions questionnaire assessments. Patients with a
higher baseline LCSS had a greater survival beneﬁt on the
necitumumab arm. Chemotherapy exposure was similar in
both treatment arms; 51% of patients on the necitumumab
plus gemcitabine-cisplatin arm continued on single-agent
necitumumab. The most frequent grade 4 adverse events
were neutropenia (6.1% versus 7.9%) and thrombocyto-
penia (3.2% versus 4.3%) in the necitumumab plus
gemcitabine-cisplatin versus gemcitabine-cisplatin arms,
respectively. Hospitalizations were slightly higher with
necitumumab plus gemcitabine-cisplatin (36.4%) than with
gemcitabine-cisplatin (34.0%).
Conclusions: The addition of necitumumab to gemcitabine-
cisplatin was well tolerated, did not negatively affect HRQoL
or toxicity, and particularly beneﬁted patients with more
severe baseline symptoms or lower HRQoL.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The majority of patients with non–small cell lung
cancer (NSCLC) present with locally advanced unresect-
able or metastatic disease and nearly all present with
serious symptoms, including fatigue, loss of appetite,
dyspnea, cough, and pain.1–3 In addition, compared with
patients with NSCLC characterized by nonsquamous
histologic features, patients with squamous NSCLC tend
to be older and report a higher prevalence of concomitant
diseases.4–6 Thus, avoiding a heavy toxicity burden and
detrimental effects on patients’ health-related quality of
life (HRQoL) are important considerations in developing
new treatments for patients with squamous NSCLC.7,8
Squamous and nonsquamous NSCLC differ in terms of
genetics and some therapeutic options. Whereas many
ﬁrst-line treatment options exist for patients with non-
squamous disease, the ﬁrst-line options for patients with
squamous NSCLC are limited and have remained essen-
tially unchanged over the past two decades.9,10 The rec-
ommended ﬁrst-line therapy for squamous NSCLC is
generally a platinum doublet chemotherapy regimen(including cisplatin or carboplatin and a chemotherapy
agent such as gemcitabine, a taxane, or vinorelbine).11,12
Patients with advanced or metastatic squamous NSCLC
treated with current standard ﬁrst-line chemotherapy
options have a median survival time in the range of 9.5 to
10.8 months, which is somewhat shorter than the median
overall survival described for patients with advanced or
metastatic nonsquamousNSCLC (10.3–12.4months).13–17
Necitumumab is a second-generation, recombinant
human immunoglobulin G1 epidermal growth factor re-
ceptor (EGFR) antibody. In the phase 3 SQUIRE trial, the
addition of necitumumab to the standard ﬁrst-line
chemotherapy doublet of gemcitabine and cisplatin
resulted in a statistically signiﬁcant improvement in
overall survival in patients with squamous NSCLC (strat-
iﬁed hazard ratio [HR] ¼ 0.84, 95% conﬁdence interval
[CI]: 0.74–0.96; p ¼ 0.01, median survival 11.5 months
[10.4–12.6] versus 9.9months [8.9–11.1], respectively).18
Here we present HRQoL results from the SQUIRE trial and
focus on patient-reported symptoms and health status as
measured by the Lung Cancer Symptom Scale (LCSS) and
the European Quality of Life Five-Dimensions (EQ-5D)
questionnaire, respectively, as well as physician-reported
Eastern Cooperative Oncology Group performance status
(ECOG PS) and drug tolerability.
Patients and Methods
Patient Population, Study Design, and
Treatment
Full details of the SQUIRE study design and patient
eligibility criteria have been previously published.18
Brieﬂy, patients with ECOG PS 0–2 and stage IV squa-
mous NSCLC were randomized 1:1 to receive necitumu-
mab (800 mg absolute dose intravenously [IV] on days 1
and 8) plus gemcitabine-cisplatin (gemcitabine ¼ 1250
mg/m2 IV on days 1 and 8; cisplatin ¼ 75 mg/m2 IV on
day 1) or gemcitabine-cisplatin alone (every 21 days)
for up to six cycles. Patients treated with necitumumab
plus gemcitabine-cisplatin with no disease progression
continued necitumumab single-agent therapy until disease
progression. The primary end point was overall survival.
Secondary end points included evaluation of patient-
reported symptoms, health status, and safety proﬁle. The
studywas conducted in compliancewith the Declaration of
Helsinki, International Conference on Harmonisation
Guidelines for Good Clinical Practice, and applicable local
regulations. The protocol was approved by the ethics
committees of all participating centers, and all patients
provided written informed consent before study entry.
Health-Related Quality of Life
The HRQoL analyses focused on patient-reported
symptoms as measured by the LCSS and a broader
810 Reck et al Journal of Thoracic Oncology Vol. 11 No. 6assessment of health status as measured by the EQ-5D,
in addition to physician-reported ECOG PS.19–21 LCSS,
EQ-5D, and ECOG PS scores were analyzed for all pa-
tients in the intention-to-treat population with a baseline
and at least one post-baseline assessment.
ECOG PS was evaluated in both arms by a physician
at baseline (before treatment), before the start of each
cycle, at the end of treatment, and during a 30-day safety
follow-up visit. ECOG PS results were summarized using
frequency distributions at baseline for cycles 1 to 6 and
at the end of therapy. Time to ﬁrst deterioration of ECOG
PS by at least one level from baseline was estimated
using a Cox proportional hazards model. For each patient
who was not known to have had a deterioration, time to
deterioration was censored at the last ECOG PS assess-
ment date.
The LCSS and EQ-5D were administered in both arms
at baseline, at the beginning of every cycle (2–6), and
every 6 weeks thereafter until disease progression. At
each scheduled assessment, the LCSS was completed
before the EQ-5D. LCSS and EQ-5D data were analyzed
by visit as assessments were performed whether a visit
was for treatment (cycle) or for follow-up for disease
progression.
The LCSS consists of nine items regarding the
severity of six major lung cancer symptoms (loss of
appetite, fatigue, cough, dyspnea, hemoptysis, and pain)
and three global measures (interference with normal
activity, quality of life, overall lung cancer symptoms).
For each of the nine LCSS items, the patient’s response is
scored from 0 to 100, with lower scores representing
lower severity. In addition to the nine individual items’
scores, three summary indices were calculated: the
average symptom burden index, which was deﬁned as
the mean across the six symptom-speciﬁc items; the
global three-item composite index, which was deﬁned as
the mean of the three global items; and the LCSS total
score, which was deﬁned as the mean score over all nine
items (if any of the nine items were not completed, the
total score was treated as missing). For each of the LCSS
items, mean values with standard deviations were esti-
mated for each visit. In addition, for each of the LCSS
variables, changes from baseline scores for every post-
baseline assessment were obtained. On the basis of work
by de Marinis et al.,22 a clinically meaningful change
was deﬁned for each visit as at least a 15-mm change
from baseline, which is also consistent with one-half
the standard deviation of baseline scores.23,24 There-
fore, worsening was deﬁned as at least a 15-mm increase
from baseline, and an improvement was deﬁned as at
least a 15-mm decrease. Stable was deﬁned as a change
less than 15 mm or no change.
Time to deterioration was estimated using the
Kaplan-Meier method and compared between treatmentarms using a log-rank test. Additionally, HR and its
95% CI were estimated from the Cox proportional
hazards model.25 For each patient who was not known
to have had a deterioration, time to deterioration
was censored at the date of the patient’s last LCSS
assessment.
The EQ-5D comprises a descriptive system, a three-
level assessment (no problem, some problem, and se-
vere problem) of ﬁve dimensions (mobility, pain and
discomfort, anxiety and depression, self-care, and usual
activities), plus a visual analogue scale (VAS) rating of
the patient’s overall health state on a scale of 0 to 100,
where 0 is the worst imaginable health state and 100 is
the best imaginable health state. The mean VAS scores
with standard deviations and the frequencies of patients
experiencing no problems, some problems, and severe
problems for each of the EQ-5D dimensions were sum-
marized descriptively by visit.
In addition to the LCSS analyses already described, a
novel analysis was undertaken to evaluate the outcomes
of patients with more severe baseline LCSS scores
relative to those of patients with less severe baseline
LCSS scores. This analysis deﬁned the maximum severity
score (MSS) for each LCSS assessment as the maximum
(worst) score among the nine individual LCSS items.
MSS at baseline was used to categorize patients into two
groups: those with high LCSS severity (MSS  median)
and those with low severity (MSS < median).26 Vari-
ables for mean maximum improvement in MSS and
other LCSS items over baseline were compared between
treatment arms by least squares means (analysis of
covariance).
Tolerability
Tolerability was determined by study treatment
exposure, the percentage of patients receiving necitu-
mumab continuation therapy, reported adverse events
(according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0),
and discontinuation of treatment for adverse events.
Tolerability was evaluated in the safety population. Pa-
tients were assessed regularly for potential occurrence
of adverse events from the time the patient signed the
informed consent document until 30 days after the last
dose of study therapy, or until resolution or stabilization
of a serious adverse event or study therapy-related
adverse event.
Tolerability and hospitalization results are presented
by phase of treatment. Chemotherapy phase refers to the
period during which patients received chemotherapy in
both arms; continuation refers to the period after
discontinuation of chemotherapy when patients on the
necitumumab plus gemcitabine-cisplatin arm continued
single-agent necitumumab.
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Patient and Disease Characteristics
The intention-to-treat population comprised 1093
patients who were randomly assigned to receive neci-
tumumab plus gemcitabine-cisplatin (n ¼ 545) or
gemcitabine-cisplatin (n ¼ 548). Seven patients in each
group did not receive the study treatment; thus, the
safety population comprised 1079 patients. Baseline
patient and disease characteristics were well balanced
between treatment arms and have been previously
reported.18Health-Related Quality of Life
Results are shown through visit 14; after visit 14 only
a small number of patients were available for the
analysis.
ECOG PS. Of the 1093 patients in SQUIRE, 96 (9%) had a
baseline ECOG PS of 2.18 The percentage of patients with
an ECOG PS of 0–1 or 2 at each cycle was comparable
between arms of the trial during the chemotherapy
phase (see Supplementary Fig., Supplementary Digital
Content 1). Most patients maintained their baseline
ECOG PS throughout chemotherapy, with only a small
percentage of patients (6.2% in the necitumumab plus
gemcitabine-cisplatin arm and 3.9% patients in the
gemcitabine-cisplatin arm) deteriorating from an ECOG
score of 0–1 to 2.
LCSS. Of the 545 patients in the necitumumab plus
gemcitabine-cisplatin arm, 481 (88.3%) had a baseline
assessment and at least one completed post-baselineTable 1. Responses for Individual LCSS Items at Baseline by EC
ECOG PS 0–1
Neci þ Gem-Cis
n ¼ 496
Gem-
n ¼ 5
n Median (Q1–Q3) n
Loss of appetite 467 25.0 (7.0–48.0) 476
Fatigue 469 34.0 (12.0–53.0) 473
Cough 470 23.0 (7.0–51.0) 474
Dyspnea 473 21.0 (6.0–50.0) 472
Hemoptysis 471 0.0 (0.0–5.0) 473
Pain 471 9.0 (1.0–37.0) 475
Average symptom burden index 462 22.5 (13.7–38.2) 471
Overall lung cancer symptoms 471 23.0 (6.0–49.0) 470
Interference with normal activity 471 28.0 (7.0–51.0) 475
Quality of life today 470 38.0 (15.0–53.0) 475
Global three–item composite index 470 31.0 (15.0–50.3) 471
LCSS total score 460 25.3 (14.2–40.4) 466
MSS 475 52.0 (31.0–75.0) 478
LCSS, Lung Cancer Symptom Scale; ECOG, Eastern Cooperative Oncology Group; N
cisplatin; MSS, maximum severity score.LCSS assessment. In the gemcitabine-cisplatin arm, 482
(88.0%) of the 548 patients had a baseline assessment
and at least one completed postbaseline LCSS assess-
ment. Compliance by visit can be found in Supplementary
Digital Content 2. The median baseline LCSS scores
shown in Table 1 suggest that patients generally reported
moderate-to-high symptoms, interference with normal
activities, and impact on quality of life, which may be seen
as typical of ﬁrst-line squamous NSCLC. Patients with an
ECOG PS of 2 reported numerically higher symptoms for
all LCSS variables, with the exception of hemoptysis
(which occurred infrequently at all PS levels and on both
study arms). Figure 1 shows LCSS response by assess-
ment time point (visit). Over time, of those patients still in
the study, most in both of the study arms had stable
symptoms compared to baseline, and a similar pattern of
response was seen for LCSS global items and LCSS total
score. The proportion of patients with improved or stable
scores compared with the baseline versus deterioration
or missing was greater for the pain item in the necitu-
mumab plus gemcitabine-cisplatin arm than in the
gemcitabine-cisplatin arm at visits 5 (p ¼ 0.0281) and 6
(p ¼ 0.0325); otherwise, the responses were similar be-
tween treatment arms.
Figure 2 shows the forest plot of HRs and 95% CIs
for time to deterioration over the entire assessment
period for each of the 12 LCSS variables as well as for
ECOG PS. None of the 95% CIs excluded an HR of 1.0,
suggesting no compelling differences between the two
trial arms.
EQ-5D. Of the 545 patients in the necitumumab plus
gemcitabine-cisplatin arm, 484 (88.8%) had a baselineOG Performance Status
ECOG PS 2
Cis
00
Neci þ Gem-Cis
n ¼ 49
Gem-Cis
n ¼ 47
Median (Q1–Q3) n Median (Q1–Q3) n Median (Q1–Q3)
20.0 (5.0–46.0) 47 29.0 (5.0–50.0) 45 37.0 (11.0–56.0)
34.0 (10.0–52.0) 48 46.0 (30.5–67.0) 45 53.0 (40.0–72.0)
26.0 (7.0–51.0) 48 39.0 (7.5–53.5) 46 28.0 (10.0–52.0)
22.0 (4.0–50.0) 47 45.0 (4.0–70.0) 45 50.0 (21.0–72.0)
0.0 (0.0–4.0) 47 0.0 (0.0–4.0) 46 0.5 (0.0–4.0)
10.0 (2.0–35.0) 47 26.0 (2.0–55.0) 46 32.5 (8.0–56.0)
23.0 (12.2–35.2) 46 33.1 (21.0–43.8) 44 33.3 (20.8–48.2)
23.0 (5.0–47.0) 47 38.0 (10.0–67.0) 46 35.5 (15.0–69.0)
33.0 (10.0–56.0) 48 48.0 (20.0–75.5) 46 53.5 (34.0–76.0)
40.0 (17.0–53.0) 47 52.0 (31.0–70.0) 46 50.5 (36.0–65.0)
33.0 (16.0–51.0) 47 50.0 (26.3–63.7) 46 49.7 (33.0–66.0)
26.2 (14.7–39.6) 46 37.8 (25.2–48.4) 44 40.2 (25.8–54.7)
52.0 (30.0–70.0) 48 60.5 (45.5–86.0) 46 69.5 (50.0–79.0)
eci þ Gem-Cis, necitumumab þ gemcitabine-cisplatin; Gem-Cis, gemcitabine-
Figure 1. Lung Cancer Symptom Scale responses by visit. (A) Six major lung cancer symptoms, (B) three global items, and
(C) LCSS total score- mean score over all 9 items.
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EQ-5D assessment. In the gemcitabine-cisplatin arm,
489 (89.2%) of the 548 patients had a baseline assess-
ment and at least one completed post-baseline EQ-5D
assessment. Compliance by visit can be found in
Supplementary Digital Content 3. Mean EQ-5D VAS scores
were generally consistent between treatment groups
at baseline and at subsequent visits (see Supplementary
Fig., Supplementary Digital Content 4A). Supplementary
Digital Content 4B shows the percentage of patients ex-
periencing no problems, some problems, and severe
problems for eachof theEQ-5Ddimensions (mobility, pain
and discomfort, anxiety and depression, self-care, and
usual activities). At baseline, the severity of problems
was similar in both arms of the study and relatively
few patients (6.2% in both arms) experienced severeproblems. The percentages of patients experiencing no
problems, some problems, and severe problemswere also
broadly similar between treatment groups at subsequent
visits (see Supplementary Digital Content 4B).
Outcomes by Baseline LCSS Severity. The median
baseline MSS on each study arm was 60. Baseline
prognostic factors were generally similar for the sub-
groups of patients with a median baseline MSS of at
least 60 and MSS less than 60 (see Supplementary
Table, Supplementary Digital Content 5). The overall
survival HRs for the necitumumab plus gemcitabine-
cisplatin arm versus the gemcitabine-cisplatin arm
were 0.67 (p < 0.001) for patients with a baseline MSS
of at least 60 and 1.06 (p ¼ 0.547) for patients with a
baseline MSS less than 60 (Fig. 3A). The respective
Figure 1. (continued).
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for patients with a baseline MSS of at least 60 and 1.07
(p ¼ 0.493) for patients with a baseline MSS less than
60 (Fig. 3B).
Among patients with a baseline MSS of at least 60,
the maximum improvement over baseline in the dys-
pnea, pain, and quality of life items of the LCSS was
statistically signiﬁcantly greater for the necitumumab
plus gemcitabine-cisplatin arm than for the
gemcitabine-cisplatin arm (see Supplementary Table,
Supplementary Digital Content 6). Also among patientswith a baseline MSS of at least 60, the addition of
necitumumab to gemcitabine-cisplatin statistically
signiﬁcantly delayed both the ﬁrst worsening of pain
(median 16.6 versus 5.7 months) and dyspnea (median
9.3 versus 5.7 months) as compared to the gemcitabine-
cisplatin arm. Among patients with a baseline MSS less
than 60, there were no signiﬁcant differences in the
corresponding items. For other LCSS items not shown
in Supplementary Digital Content 6, there were no
statistically signiﬁcant differences observed in either
MSS group.
Figure 2. Forest plot of hazard ratios and 95% conﬁdence intervals for time to deterioration for the Lung Cancer Symptom
Scale and Eastern Cooperative Oncology Group performance status.
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Treatment Exposure. Data for the necitumumab plus
gemcitabine-cisplatin arm are presented for the chemo-
therapy phase (maximum of six cycles) and for the
necitumumab continuation phase separately to allow
for appropriate comparison with the gemcitabine-
cisplatin arm. Exposure to chemotherapy was similar
in both treatment arms (see Supplementary Table,
Supplementary Digital Content 7). The proportion of
patients completing six cycles of therapy with gemcita-
bine was 55% in the necitumumab plus gemcitabine-
cisplatin arm and 48% in the gemcitabine-cisplatin
arm; with cisplatin, the proportion was 53% in the
necitumumab plus gemcitabine-cisplatin arm and 46%
in the gemcitabine-cisplatin arm. Of the 538 patients
who received necitumumab plus gemcitabine-cisplatin,
275 (51%) continued on necitumumab continuation
monotherapy. The maximum number of cycles of neci-
tumumab reached by the cutoff date was 45.
Reported Adverse Events. During the chemotherapy
phase of the trial, 68% of patients in the necitumumab
plus gemcitabine-cisplatin arm and 62% of patients in the
gemcitabine-cisplatin arm experienced grade 3 or higher
adverse events; during the necitumumab continuation
phase of the trial, 29% of patients experienced grade 3 orhigher adverse events. Rates of treatment discontinua-
tion due to adverse events in the chemotherapy phase of
the trial were slightly higher in the necitumumab plus
gemcitabine-cisplatin arm than in the gemcitabine-
cisplatin arm (28% versus 25%, respectively) and low
in the necitumumab continuation phase (6%) (see
Supplementary Table, Supplementary Digital Content 8).
Rates of adverse events with an outcome of death
(excluding fatal cases of disease progression) during the
chemotherapy phase were slightly lower in the necitu-
mumab plus gemcitabine-cisplatin arm than in the
gemcitabine-cisplatin arm (6% versus 7%, respectively).
To further explore safety in the chemotherapy and
necitumumab continuation phases of the trial, adverse
events of interest were deﬁned on the basis of the
known safety proﬁles of other EGFR antibodies and/or
prior clinical experience with necitumumab (Table 2).
More patients in the necitumumab plus gemcitabine-
cisplatin arm had grade 3 or 4 hypomagnesemia (8.9%
of patients in the necitumumab plus gemcitabine-
cisplatin arm versus 1.1% in the gemcitabine-cisplatin
arm) and grade 3 rash (5.6% versus 0.4%) during the
chemotherapy phase of the trial. The grade 4 adverse
events occurring at the highest rates during the
chemotherapy phase of the trial were neutropenia and
thrombocytopenia. The incidences of both were slightly
Figure 3. (A) Kaplan-Meier curves for overall survival above and below the median baseline maximum severity score (MSS),
(B) Kaplan-Meier curves for progression-free survival above and below the median baseline MSS. Note that 60 is the median
MSS in each study arm.
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necitumumab plus gemcitabine-cisplatin arm (neu-
tropenia 7.9% versus 6.1%; thrombocytopenia 4.3%
versus 3.2%, respectively). There were no clinically
relevant differences in the rate of fatal venous or arterial
thromboembolic events between treatment arms during
the chemotherapy phase of the trial.
Hospitalizations. Table 3 summarizes hospitalizations of
patients during both the chemotherapy and necitumumab
continuation phases of the study. The percentage of
patients hospitalized in general was slightly higher in the
necitumumab plus gemcitabine-cisplatin arm than in the
gemcitabine-cisplatin arm during the chemotherapy
phase. During the necitumumab continuation phase of the
trial, the percentage of patients hospitalized was much
lower than during the chemotherapy phase of the trial.
Treatment-Emergent Adverse Events Leading to
Hospitalization. Treatment-emergent adverse events
leading to hospitalization during both the chemotherapyand necitumumab continuation phases of the trial are
presented in Supplementary Digital Content 9. The per-
centage of patients with treatment-emergent adverse
events leading to hospitalization was slightly higher in the
necitumumab plus gemcitabine-cisplatin arm than in the
gemcitabine-cisplatin arm (32.5%versus 29.2%). Notably,
the percentage of patients with treatment-emergent
adverse events leading to hospitalization in the necitu-
mumab continuation phase of the trial was low (14.2%).
Discussion
Prolongation of life along with maintenance of
HRQoL and palliation of symptoms are the major goals
for treatment of advanced squamous NSCLC. The
SQUIRE trial established that in a patient population
with a heavy metastatic disease burden (approximately
55% of patients with metastases to >2 organ systems),
generally moderate to high symptoms, and an ECOG PS
of 0–2, the addition of necitumumab to ﬁrst-line
chemotherapy improved overall survival in patients
with advanced squamous NSCLC.18 The ﬁndings
Table 2. Select Treatment-Emergent Adverse Events of Special Interest Occurring in the SQUIRE Safety Population
Event Categorya
Chemotherapy Phase Continuation Phase
Neci þ Gem-Cis
(n ¼ 538)
% Patients
Gem-Cis
(n ¼ 541)
% Patients
Neci
(n ¼ 275)
% Patients
Gr 1 Gr 2 Gr 3 Gr 4 Gr 5 Gr 1 Gr 2 Gr 3 Gr 4 Gr 5 Gr 1 Gr 2 Gr 3 Gr 4 Gr 5
Neutropenia 4.1 15.2 18.2 6.1 0 3.1 15.2 19.6 7.9 0 0 0 0 0.4 0
Febrile neutropenia 0 0.2 0.4 0.2 0 0 0.2 1.1 0.2 0 0.4 0.0 0.4 0 0
Anemia 5.9 23.8 10.0 0.4 0 6.3 28.7 10.4 0.6 0 5.5 7.3 1.1 0 0
Thrombocytopenia 5.2 6.1 7.1 3.2 0 7.2 9.1 6.5 4.3 0 1.8 0.4 0 0 0
Fatigue 15.6 18.2 6.7 0.2 0 16.6 18.9 6.7 0.4 0 2.5 5.8 0.7 0 0
Hypomagnesemia 9.5 11.7 6.9 2.0 0 8.7 5.9 1.1 0 0 8.0 5.5 1.8 0.7 0
Skin reactions 39.2 32.3 6.3 0 0 8.9 2.4 0.6 0 0 14.2 12.7 4.7 0 0
Rash 39.6 30.1 5.6 0 0 7.9 1.8 0.4 0 0 12.0 9.5 4.0 0 0
Hypersensitivity/infusion related reaction 0.6 0.6 0.4 0 0 1.7 0.4 0 0 0 0 0 0 0 0
Conjunctivitis 3.9 1.7 0 0 0 1.5 0.7 0 0 0 2.5 1.5 0.7 0 0
Interstitial lung disease (pneumonitis) 0.2 0.4 0.2 0 0 0 0.2 0.6 0 0 0 0 0 0 0.4
Arterial thromboembolic events 0.6 0.7 1.7 0.9 0.4 0.2 1.7 1.5 0.4 0.2 0 0.4 1.5 0.0 0.4
Venous thromboembolic events 1.3 2.6 3.2 1.1 0.0 0.2 2.6 0.9 1.5 0.2 0 0.7 1.1 0.4 0.4
aAdverse events of possible relevance to treatment, according to either composite categories or preferred terms (febrile neutropenia only).
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provided by the addition of necitumumab to
gemcitabine-cisplatin in the SQUIRE trial was not
accompanied by impairment of patient outcomes in
terms of HRQoL or tolerability.
In this study, most patients in both arms of the trial
were able to maintain their ECOG PS. Analysis of time to
worsening of symptoms, as measured by the LCSS data
and the patient-reported EQ-5D analysis, did not support a
consistent or compelling difference between the two trialTable 3. Summary of Hospitalizations in the SQUIRE Safety Po
Chemothera
Neci þ Gem
(n ¼ 538)
Patients hospitalized, n (%)a 196 (36.4)
Hospitalizations due to an AEa 167 (31.0)
Total duration of hospitalization for any reason, d
n 193
Mean ± SD 14.4 (14.08)
Median 11.0
Total duration of hospitalization due to AEs, d
n 164
Mean ± SD 12.8 (11.34)
Median 9.0
No. hospitalizations due to AEs, n (%)
1 114 (21.2)
2 40 (7.4)
3 9 (1.7)
4 4 (0.7)
aEach patient may have more than one hospitalization.
SQUIRE, First-Line Treatment of Participants With Stage IV Squamous Non–Small
Cis, necitumumab þ gemcitabine-cisplatin; Gem-Cis, gemcitabine-cisplatin; SD,arms. Although the validity of HRQoL data is often
threatenedbymissingdata,27 this trial reported ahigh rate
of compliance for completion of both assessments. The
additional analyses of outcomes by baseline LCSS severity
suggested that the addition of necitumumab to
gemcitabine-cisplatin provided the greatest survival
beneﬁt in patients with more severe baseline LCSS scores.
Moreover, the addition of necitumumab to gemcitabine-
cisplatin improved key LCSS items among patients
with a higher severity of baseline LCSS scores. Thispulation
py Phase
p Value
Continuation Phase
-Cis Gem-Cis
(n ¼ 541)
Neci
(n ¼ 275)
184 (34.0) 0.4082 43 (15.6)
146 (27.0) 0.1589 34 (12.4)
180 41
14.5 (14.67) 0.8170 9.2 (7.30)
9.0 8.0
143 33
12.2 (12.88) 0.2817 9.0 (6.33)
8.0 8.0
105 (19.4) 29 (10.5)
25 (4.6) 5 (1.8)
9 (1.7) 0
7 (1.3) 0
Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin; Neci þ Gem-
standard deviation; AE, adverse event.
June 2016 Necitumumab Tolerability and QoL in SQUIRE 817symptomatic efﬁcacy is of particular interest for the
squamous lung cancerpatient population as these patients
tend to experience a high level of co-morbidities.4,28
The balance among toxicity, efﬁcacy, and quality
of life plays a critical role in determining a clinically
meaningful treatment outcome.8 It is of note that pa-
tients in the gemcitabine-cisplatin arm of this study were
permitted to undergo study treatment for a maximum of
six cycles, whereas patients in the necitumumab plus
gemcitabine-cisplatin arm could receive amaximum of six
cycles of chemotherapy in combination with necitumu-
mab, and patients with a response of stable disease or
better could continue to receive single-agent necitumu-
mab until withdrawal criteria were met. As a result, the
treatment period was longer in the necitumumab plus
gemcitabine-cisplatin arm. The addition of necitumumab
to chemotherapy did not affect the administration of
chemotherapy at the recommended dose and schedule,
did not cause an increase in the rate of discontinuation
due to drug-related toxicities, and did not cause an in-
crease in adverse events (with the exception of expected
EGFR inhibitor class effects—skin reactions/rash and
hypomagnesemia).29–32 Furthermore, there were no
notable differences between arms of the trial in the rates
of grade 4 adverse events, which are of particular interest
because they tend to incur higher cost owing to their as-
sociation with hospitalizations and other resource use.
This report combines physician-reported adverse
event collection (an objective evaluation of disease- and
symptom-related toxicities), ECOG PS and patient-
reported outcomes (a reﬂection of symptom burdens
and functional changes directly experienced by patients)
to capture a comprehensive proﬁle of the impact of
necitumumab treatment. The well-tolerated safety pro-
ﬁle and the LCSS and EQ-5D analyses show that adding
necitumumab to gemcitabine-cisplatin did not have an
impact, overall, on the deterioration of patients’ HRQoL
and suggest that the most beneﬁt is obtained by patients
with higher severity of symptoms or poorer overall
quality of life at the start of treatment.
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